-Wall Street Journal
Goldman Sachs Maintains Buy on Kronos Bio, Lowers Price Target to $14
Goldman Sachs analyst Salveen Richter maintains Kronos Bio (NASDAQ:KRON) with a Buy and lowers the price target from $25 to $14.
Related Posts
Overview Of Value Stocks In The Basic Materials Sector
The Meaning Behind Value Stocks A value stock traditionally has a lower price when compared to stock prices…
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
Fastenal (NASDAQ:FAST) has outperformed the market over the past 5 years by 8.29% on an annualized basis producing an average annual return of 19.07%. Currently, Fastenal has a market capitalization of $29.57 billion.
Reddit Launches ‘Collectible Avatars’ On Polygon (MATIC) Blockchain
Social networking platform Reddit has launched a new Collectible Avatar market that is based on the Polygon (CRYPTO: MATIC) blockchain.